| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5833682 | International Immunopharmacology | 2011 | 8 Pages |
Abstract
⺠PBMC from some healthy subjects strongly react with TNFα-blocker in vitro. ⺠Infliximab (I) and etanercept (E) differ in their action on immunocompetent cells. ⺠I. decreases, E. enhances TNFα-concentrations in PBMC-supernatants. ⺠Both enhance IL-10, IL-5 and IL-13 production (Th2-reactivity). ⺠Cytokine production and proliferation of PBMC show strong inter-individual variability.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Firas Thaher, Sandra Plankenhorn, Reinhild Klein,